Lack of Mask Mandates Leaves Cancer Patients Feeling Unprotected
Cancer patients have voiced concerns about a lack of masking at cancer centers and have reported being harassed for wearing masks in public.
Cancer patients have voiced concerns about a lack of masking at cancer centers and have reported being harassed for wearing masks in public.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
An update to active surveillance recommendations has some physicians concerned.
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.